期刊
ATHEROSCLEROSIS
卷 194, 期 2, 页码 E43-E51出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2006.08.023
关键词
Coronary artery disease; Diabetes mellitus; Statin; Glucose tolerance; Adiponectin; Impaired glucose tolerance
资金
- Ministry of Education, Science and Culture, Tokyo [C(2)-17590753]
- Smoking Research Foundation, Tokyo
- Japan Heart Foundation, Tokyo
- Ministry of Health, Labor and Welfare, Tokyo [14C-4]
Reduced incidence of type-2 diabetes has been shown in patients treated with pravastatin. Adiponectin can exhibit beneficial effects on glucose metabolism. We investigated whether pravastatin could improve glucose tolerance associated with increasing adiponectin levels in patients with impaired glucose tolerance (IGT). This study consisted of 40 coronary artery disease (CAD) patients with IGT assessed by oral glucose tolerance test (OGTT). Patients were randomized to receive pravastatin (n = 20) or no lipid-lowering medications (control group, n = 20) for 6 months, after which OGTT was repeated and adiponectin levels were measured. Pravastatin treatment significantly decreased levels of total cholesterol (16%), low-density lipoprotein cholesterol (23%) and high-sensitivity C-reactive protein (37%) (p < 0.01, respectively). At 2 h in OGTT, pravastatin significantly improved hyperglycemia (-14%) and hyperinsulinemia (-23%). Pravastatin treatment significantly elevated plasma adiponectin levels (35%; p < 0.001) but not in the control group. The glucose reduction at 2 h post-OGTT was significantly associated with increased levels of adiponectin (r = -0.462; p = 0.003). Pravastatin treatment is an independent predictor for improvement of post-loaded hyperglycemia (odds ratio; 5.7; 95% confidence interval 1.7-19.3; p = 0.003) and achieved beneficial conversion from IGT to normal glucose tolerance (40%; p = 0.03). Pravastatin exhibits beneficial effects on glucose metabolism especially in the postprandial state associated with increasing plasma adiponectin levels in CAD patients with IGT. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据